Coherus Oncology (CHRS) Projected to Post Quarterly Earnings on Monday

Coherus Oncology (NASDAQ:CHRS) is expected to be issuing its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($0.31) per share and revenue of $14.0930 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 5:00 PM ET.

Coherus Oncology Stock Performance

Shares of CHRS stock opened at $1.67 on Monday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.23 and a current ratio of 1.24. The firm has a market cap of $249.61 million, a price-to-earnings ratio of 1.26 and a beta of 1.05. Coherus Oncology has a 52 week low of $0.71 and a 52 week high of $2.62. The firm’s 50-day simple moving average is $1.73 and its two-hundred day simple moving average is $1.52.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Wall Street Zen upgraded Coherus Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Oppenheimer began coverage on Coherus Oncology in a research report on Thursday, January 22nd. They set an “outperform” rating and a $10.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Coherus Oncology currently has a consensus rating of “Hold” and a consensus price target of $5.51.

Hedge Funds Weigh In On Coherus Oncology

Large investors have recently modified their holdings of the company. Quarry LP bought a new stake in Coherus Oncology during the 3rd quarter worth approximately $26,000. Blair William & Co. IL bought a new position in Coherus Oncology in the 4th quarter valued at $27,000. BNP Paribas Financial Markets grew its position in shares of Coherus Oncology by 108.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 26,620 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 13,832 shares in the last quarter. Corient Private Wealth LLC increased its holdings in shares of Coherus Oncology by 20.0% in the second quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 10,000 shares during the period. Finally, Jane Street Group LLC purchased a new stake in shares of Coherus Oncology in the second quarter worth $46,000. 72.82% of the stock is currently owned by institutional investors.

Coherus Oncology Company Profile

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.